Hyperion DeFi (NASDAQ:HYPD) and 180 Life Sciences (NASDAQ:ATNFW) Financial Review

180 Life Sciences (NASDAQ:ATNFW) and Hyperion DeFi (NASDAQ:HYPD) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, valuation, analyst recommendations and earnings.

Analyst Ratings

This is a breakdown of current recommendations for 180 Life Sciences and Hyperion DeFi, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
180 Life Sciences	0	0	0	0	0.00
Hyperion DeFi	1	4	0	0	1.80

Hyperion DeFi has a consensus target price of $2.00, indicating a potential downside of 72.49%. Given Hyperion DeFi’s stronger consensus rating and higher possible upside, analysts clearly believe Hyperion DeFi is more favorable than 180 Life Sciences.

Institutional & Insider Ownership

25.8% of Hyperion DeFi shares are owned by institutional investors. 10.9% of Hyperion DeFi shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares 180 Life Sciences and Hyperion DeFi’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
180 Life Sciences	N/A	N/A	N/A
Hyperion DeFi	-62,238.41%	-876.25%	-181.67%

Earnings & Valuation

This table compares 180 Life Sciences and Hyperion DeFi”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
180 Life Sciences	N/A	N/A	N/A	N/A	N/A
Hyperion DeFi	$60,000.00	843.32	-$49.82 million	($58.40)	-0.12

180 Life Sciences has higher earnings, but lower revenue than Hyperion DeFi.

Summary

Hyperion DeFi beats 180 Life Sciences on 5 of the 8 factors compared between the two stocks.

About 180 Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.